|
|
 |
 |
|
|
|
According to WHO predictions, diseases of the central nervous system will constitute an increasing medical need this century, attributable to an exponential increase of these diseases after the age of 65 combined with an aging population. To date, available therapeutic treatments are still unsatisfactory for the majority of CNS diseases.
Our research in CNS diseases therefore focuses on novel treatment concepts for the major neurodegenerative disorders, Alzheimer’s and Parkinson’s disease, prominent consequences of the aging population. An additional focus lies on chronic pain, a condition for which medical attention is sought most frequently.
New molecular targets, such as ion channels and G-protein coupled receptors (GPCRs), which are involved in pain transduction pathways and have been validated in neuropathic and inflammatory pain models, form the basis for our drug discovery efforts in the chronic pain indication. Our drug discovery activities in the indication migraine address a new mechanism of action to interfere with cerebral vasodilation for which we have obtained clinical proof of concept.
|
|
|
|
|
|
Our research efforts to interfere with disease progression in Alzheimer’s and Parkinson’s disease focus on targets established by pathology and genetics. Our activities in Alzheimer’s disease are, for example, aimed at reducing amounts of the amyloid-beta peptide, the major mediator of this fatal disorder and additionally searching for pro-cognitive therapies beyond acetylcholine restoration in this disease. Moreover, we are investigating approaches for reducing treatment-induced motor complications (dyskinesias), a major medical problem for patients with late stage Parkinson’s disease. |
|
© 1999 Boehringer
Ingelheim GmbH, Germany. All rights reserved.
Imprint | Terms
of use
Last update: 27.03.2007
|
|
|
|
